Antibodies
9 January 2012
Biocon Announces Positive Efficacy Data with its Novel Monoclonal Antibody Itolizumab in a Pivotal Psoriasis Study9 January 2012
Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients2 January 2012
Emergent Announces Plans for TRU-016 Program Following Termination of Collaboration with Abbott30 December 2011
Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer29 December 2011
Peregrine Provides Update on HCV Clinical Program28 December 2011
Emergent Initiates Phase 2 Study of TRU-016 in Combination with Bendamustine in Patients with Relapsed Chronic Lymphocytic Leukemia21 December 2011
Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer’s Disease From Merck21 December 2011
MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with Multiple Sclerosis20 December 2011
DiaMedica’s DM-204 for Type 2 Diabetes Successfully Humanized17 December 2011
ThromboGenics and BioInvent Complete Enrolment of Phase IIb Trial with TB-402 ahead of schedule17 December 2011
AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim14 December 2011
Profectus BioSciences, Inc. Receives $5.4M Grant to Develop a Monocolonal Antibody Against Infection by Nipah/Hendra Viruses14 December 2011
Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)13 December 2011
Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASHNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports